ZEB1 and glioblastoma: Knockdown of MALAT-1 markedly enhanced the sensitivity of multi-resistant glioblastoma cells to Temozolomide (TMZ) by decreasing the expression level of the resistance genes MDR1, MRP5, and LRP1 as well as the mesenchymal markers ZEB1, α-SMA, and fibronectin.